The Versatile Leap-In Transposase Platform: Applications in High Titer Bispecific Antibody Production and Next Generation Cell Therapies
Sponsored by ATUM
The Leap-In Transposase® Platform was launched by ATUM in 2018 for cost-effective, easily implemented stable CHO cell line development and the robust manufacturing of biologics and vaccines. Through continuous development and optimization, Leap-In Transposase has become the industry standard and saw broad application in the urgent response to SARS-CoV-2, enabling the accelerated generation of clinical materials on a timeline of mere months.
The combination of the platform’s rapid generation of bulk pools that are highly predictive of the final manufacturing clones with ATUM’s deep expertise in protein expression regulation has also been applied to the expression of complex multispecific biologics comprised of three and four chains where chain ratio balancing can be critical for robust, cost-effective manufacturing.
In this webinar, ATUM and Invenra will present a case study on the application of the Leap-In Transposase Platform for the development of stable Invenra B-Body® Bispecific Antibody expressing CHO lines that generated unprecedented antibody titer with minimal side-product though the optimization of chain ratios and a well-considered clone selection approach. The resulting CHO lines for three separate Invenra B-Body bispecifics produced among the highest yields observed for bispecific antibody production and permitted the development of a robust, manufacturing protocol with anticipated final yields near or more than 6g/L and readily scalable to kg levels. Additionally, early-stage pools produced via Leap-In Transposase were of sufficient quality to supply preclinical studies and accelerate development. Details of the cell line development process will be described.
Finally, looking forward, we are exploring the application of the Leap-In Transposase Platform to the generation of novel, cell therapeutics. Because transposases efficiently integrate very large cargo, we are exploring the creation of therapeutics not possible with standard viral transduction methods. We will present our initial data on this topic and thoughts about future directions.
Learning Objective:
• How the leap-In platform works for chain ratio balancing for bispecifics & multispecifics
Privacy Policy
